Swedish Orphan Biovitrum AB (MEX:SOBI N) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SOBI N Swedish Orphan Biovitrum AB MEX:SOBI N
87 GF Score
Price MXN523.55
GF Value MXN433.35
! 5 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MEX:SOBI N
87GF Score
Swedish Orphan Biovitrum AB MEX:SOBI N
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Swedish Orphan Biovitrum AB (MEX:SOBI N) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of MXN523.55 is trading 20.8% above its estimated GF Value™ of MXN433.35.

Key valuation signals for MEX:SOBI N:

  • Short Ratio:
  • GF Value™: MXN433.35 vs. price of MXN523.55 (20.8% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the MEX:SOBI N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
87GF Score

Get the complete analysis for MEX:SOBI N

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN523.55
Price
MXN433.35
GF Value